Barcelona (Spain), December 2, 2025

To the Spanish National Securities Market Commission (CNMV)

For the purposes of complying with the provisions of Article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, **LABORATORIO REIG JOFRE, S.A.** ("**Reig Jofre**" or the "**Company**") hereby discloses the following:

OTHER RELEVANT INFORMATION

As part of its strategy to strengthen vertical integration in the field of biotechnology, REIG JOFRE has increased its stake in LEANBIO, S.L., a biotechnology company based in Barcelona dedicated to the design, development, characterization and production of biotechnology-based active pharmaceutical ingredients.

REIG JOFRE's shareholding in LEANBIO, S.L. has thus increased from the previous 47% to the current 85%, following the acquisition of shares from existing partners for a total amount of 3.5 million euros.

For this purpose, the press release titled "REIG JOFRE ACQUIRES LEANBIO AND STRENGTHENS ITS VERTICAL INTEGRATION IN BIOTECHNOLOGY" is attached, which will be distributed to national and international media outlets.

Atentamente,

D. Iñaki Frías Inchausti
Secretario no consejero del Consejo de administración
Laboratorio Reig Jofre, S.A.

Barcelona (Spain), December 2, 2025

REIG JOFRE ACQUIRES LEANBIO AND STRENGTHENS ITS VERTICAL INTEGRATION IN BIOTECHNOLOGY

- The transaction positions REIG JOFRE as a biopharmaceutical company capable of covering the full life cycle of biological medicine, from active ingredient development to final injectable products under GMP standards.

- Leanbio contributes differential technological capabilities in the development, characterization and production of recombinant proteins, antibodies, plasmid DNA and RNA technologies, strengthening the Group's value proposition.

- This milestone boosts the biotechnology ecosystem and strengthens the company's position in the European market for biological medicines and CDMO services with growing demand.

REIG JOFRE, (BME:RJF), a biopharmaceutical company listed on the Spanish stock market's continuous market that develops, manufactures, markets and distributes essential healthcare solutions, announces that it has consolidated its stake in Leanbio, a biotechnology company based in Barcelona dedicated to the design, development, characterization and production of biotechnology-based active pharmaceutical ingredients. REIG JOFRE's shareholding in LEANBIO, S.L. has thus increased from the previous 47% to the current 85%, following the acquisition of equity interests from existing shareholders for a total consideration of 3.5 million euros. The remaining 15% of the share capital remains in the hands of the founding team and specialized investors, all of them committed to driving the Spanish biotechnology ecosystem.

This transaction represents a decisive strategic step in the evolution of REIG JOFRE's business model, expanding its activity towards a biopharmaceutical structure capable of covering the research, design, process development, industrial production and scale-up phases of biological medicines. This integration positions the company as an end-to-end partner for the development of biotechnological products, a distinctive capability in the European context.

A strategic alliance that is being consolidated

The increase in REIG JOFRE's stake in Leanbio, from 47% to 85%, has been carried out through the purchase of shares from current partners for a total consideration of 3.5 million euros. This integration builds on a strategic collaboration that began in 2018 with the creation of the joint venture Syna Therapeutics, owned 50/50 by both companies for the development of biosimilars, and on REIG JOFRE's subsequent entry into Leanbio's share capital with an additional 10%.

The relationship was further strengthened in 2024 with an investment of 6.6 million euros for the construction of a new GMP-certified biotech drug substance plant in Barcelona (Sant Quirze del Vallès), a facility of around 4,000 m^2 equipped to produce recombinant proteins, antibodies, plasmid DNA and mRNA, as well as development laboratories, scale-up areas, pilot plants and quality control facilities. The plant is expected to start operations in mid-2026 and to employ more than one hundred professionals once it reaches full capacity.

More information
Inma Santa-Pau – Director of Communication - isantapau@reigjofre.com
www.reigjofre.com

In this context, the integration of Leanbio is seen as the natural evolution of a collaboration that has been consolidated over more than six years: combining the capabilities of both companies will accelerate the time-to-market of new therapies and biosimilars, supporting customers throughout the entire process, from the laboratory to the finished product.

"This transaction is a strategic milestone for REIG JOFRE. We are strengthening our vertical integration in biotechnology and consolidating a unique platform that combines Leanbio's expertise in the development of biotechnological active pharmaceutical ingredients with our industrial capabilities in sterile injectables. In this context, the integration of Leanbio positions us not only as a fully integrated player across the entire value chain, but also as a strategic competitor in a sector that we expect to continue growing over the next decade," says **Ignasi Biosca**, CEO of REIG JOFRE.

The global market for biological medicines

The CDMO (Contract Development and Manufacturing Organizations) pharmaceutical market comprises companies that provide **development and industrial manufacturing services for other innovative pharmaceutical firms**. These services include, among others, process development, the manufacturing of active ingredients and finished products under GMP standards, and industrial scale-up. The prevailing trend in the sector is for innovative companies to focus on **preclinical and clinical research** stages, relying on **specialized CDMOs** for product development in the early clinical phases and for the subsequent industrial scale-up required for commercial phases in case of success.

In this context, the global CDMO pharmaceutical market, driven by the sustained growth of biological medicines, is expanding. According to Fortune Business Insights, the global CDMO/CMO market currently exceeds USD 238 billion and could reach USD 465 billion by 2032. In the specific field of biologics, recent studies by Precedence Research estimate the biologics CDMO market at around USD 22—25 billion in 2025, with forecasts of more than USD 90 billion by 2034, supported by an annual growth rate above 15%. In Europe, the pharmaceutical CDMO market is also on an upward trend: a 2025 report published by GlobeNewswire estimates it could reach USD 70 billion by 2034.

In this environment of global and European expansion, the integration of Leanbio positions REIG JOFRE in a strategic segment, aligned with the capacity, specialization and scalability needs demanded by the biopharmaceutical industry of the future.

Leanbio: a key biotech platform in a growing market

Leanbio, founded in 2014 by Dr. Andreu Soldevila and Albert Font, is a biopharmaceutical CDMO specialized in end-to-end development and manufacturing services for biological products for the pharmaceutical and biopharmaceutical sectors. Throughout its history, the company has supported the development of more than one hundred biological candidates, from the earliest stages through to advanced clinical phases, offering integrated services that range from tech transfer and cell line and process development to analytical development, preclinical manufacturing and GMP production. This flexible, full-service model shortens timelines and optimizes development costs while maintaining high quality and regulatory compliance standards.

Following the transaction, **the founding team will retain a stake in the project and will continue to lead its growth**, working closely with the rest of the REIG JOFRE teams, combining the entrepreneurial experience of its founders with REIG JOFRE's industrial and corporate capabilities.

A key boost for the biotech ecosystem

The acquisition strengthens the national healthcare and biotechnology ecosystem by providing the infrastructure needed to drive innovation, creating highly skilled jobs and attracting international projects, while consolidating the region as a competitive hub for biopharmaceutical companies and global research centers. It also contributes to the strategic sovereignty priorities of the European Union, aimed at reinforcing industrial autonomy in the production of critical medicines.

This positioning makes REIG JOFRE a strategic partner for major pharmaceutical companies and emerging businesses seeking a fully integrated partner capable of supporting the entire development cycle of a biological product, from cell line expression to GMP clinical batches and the commercial manufacture of the final sterile product.

The transaction is fully aligned with REIG JOFRE's corporate purpose of "**universalizing the science that matters**", accelerating the development and manufacture of safe, effective and accessible biological therapies. With this integration, the company reinforces its commitment to innovative solutions that address the major challenges of the medicine of the future.

About REIG JOFRE

REIG JOFRE is a pharmaceutical company founded with a firm belief in universalizing health, bringing both basic and highly innovative solutions to people around the world. To deliver pioneering and high-impact solutions, the company relies on state-of-the-art technological production, maintains ongoing collaboration with other innovative companies, researchers and startups, and invests continuously in R&D&I. Since 1929, REIG JOFRE has been researching, developing, manufacturing and marketing pharmaceutical products that are essential for people's health, structured into three main business areas: Pharmaceutical Technologies (antibiotics and sterile injectables for hospital use), Specialty Pharmacare (dermatology and osteoarticular) and Consumer Healthcare (ENT and food supplements for health and well-being).

REIG JOFRE has 4 development and production centers in Europe, its own teams in Spain, France, Portugal, Belgium, Sweden, the United Kingdom, Poland and the Czech Republic, and an extensive network of commercial partners in more than 70 countries. The company closed 2024 with net sales of €339 million (+7% vs. 2023) and EBITDA of €38 million (+8% vs. 2023) and is listed on the Spanish Stock Exchange (BME) under the ticker RJF.